Table 6.

Biological impact of CK1δ-specific inhibitors in animal models.

Inhibitor	Effects
PF-670462	Results in a phase shift in circadian rhythm in rat, mouse, monkey, and zebrafish (Badura et al., 2007; Sprouse et al., 2009; Walton et al., 2009; Meng et al., 2010; Smadja Storz et al., 2013; Kennaway et al., 2015) Blocks amphetamine-induced locomotion in rats (Li et al., 2011a) Prevents relapse-like alcohol consumption in rats (Perreau-Lenz et al., 2012) Attenuates methamphetamine-induced locomotor activity (Bryant et al., 2009) Inhibits acute and chronic bleomycin-induced pulmonary fibrosis in mice (Keenan et al., 2018) Inhibits deterioration caused by ultraviolet B (UVB) eye irradiation in a mouse model of ulcerative colitis (Hiramoto et al., 2018) Slows down accumulation of leukemic cells in the peripheral blood and spleen in a mouse model for chronic lymphocytic leukemia (CLL), thereby preventing onset of anemia; consequently, treatment with PF-670462 significantly increases overall survival (Janovska et al., 2018)
Wager-6 PF-5006739	Attenuates opioid drug-seeking behavior in rodents (Wager et al., 2014)
SR-3029	Suppresses TPA-induced skin tumor formation in a mouse model, probably through blocking Wnt/β-catenin signaling (Su et al., 2018) Results in tumor regression in orthotopic xenotransplantation models of triple-negative breast cancer (Rosenberg et al., 2015)
Salado-20, 24, 35	Exhibit a protective effect on in vivo neurotoxicity of human TDP-43 in Drosophila (Salado et al., 2014)